Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Next Previous
Trial Profile

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE LID 3
  • Sponsors Adamas Pharmaceuticals

    • Most Recent Events

    • 17 Jun 2019 Results published in the Adamas Pharmaceuticals media release
    • 17 Jun 2019 According to an Adamas Pharmaceuticals media release, pooled data from EASE LID and EASE LID 3 were presented at the International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, and published in the Journal of Parkinson Disease, online 8th May 2019.
    • 09 Oct 2018 Results of pooled phase 3 trials (NCT02274766,NCT02136914 ) assessing Unified Dyskinesia Rating Scale (UDysRS) Parts 1B and Part 3, obtained at baseline and at Week 12, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top